EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Neoadjuvant immunotherapy in the evolving landscape of sarcoma treatment

Qiyan Cai, Yi Que, Xing Zhang iD

Journal for ImmunoTherapy of Cancer · 2024

DOI: 10.1136/jitc-2024-010074 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Qiyan Cai und 2 weiteren Autor:innen. Beteiligte Einrichtung: Melanoma and Sarcoma Medical Oncology Unit, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Sarcoma, Neoadjuvant Therapy, Immunotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Soft tissue sarcoma is characterized by its rarity and complexity, making it more difficult to conduct large clinical trials compared with other solid tumors. Also known as ‘cold tumors,’ sarcomas, especially advanced sarcomas, have poor responses to immunotherapy. Based on that, the results of two groundbreaking phase 2 clinical trials about neoadjuvant immunotherapy in patients with liposarcoma or undifferentiated pleomorphic sarcoma are encouraging. In this paper, we discuss the results of these clinical trials and the challenges we are facing to conduct neoadjuvant immunotherapy in sarcomas and call for further research to promote the development of it.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcomaNeoadjuvant TherapyImmunotherapyHumans

Stichwörter der Autor:innen

Immune Checkpoint InhibitorImmunotherapyNeoadjuvantSolid tumor

Autor:innen und Institutionen

  • Melanoma and Sarcoma Medical Oncology Unit, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
  • Department of Pediatric Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
  • Melanoma and Sarcoma Medical Oncology Unit, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China zhangxing@sysucc.org.cn.

ORCID-Profile: Xing Zhang

Zitieren

APA

Cai, Q., Que, Y., & Zhang, X. (2024). Neoadjuvant immunotherapy in the evolving landscape of sarcoma treatment. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-010074

Vancouver

Cai Q, Que Y, Zhang X. Neoadjuvant immunotherapy in the evolving landscape of sarcoma treatment. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2024-010074

BibTeX
@article{Cai2024,
  author = {Cai, Qiyan and Que, Yi and Zhang, Xing},
  title = {Neoadjuvant immunotherapy in the evolving landscape of sarcoma treatment},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  doi = {10.1136/jitc-2024-010074}
}
Kostenlos starten →